Diaceutics (LON:DXRX) Hits New 12-Month High – Still a Buy?

Diaceutics PLC (LON:DXRX) hit a new 52-week high during mid-day trading on Thursday . The stock traded as high as GBX 176.25 and last traded at GBX 172, with a volume of 512286 shares. The stock had previously closed at GBX 166.

Analyst Ratings Changes

Separately, Shore Capital lifted their price target on shares of Diaceutics from GBX 180 to GBX 215 and gave the company a “buy” rating in a research note on Thursday, January 15th. Three investment analysts have rated the stock with a Buy rating, According to MarketBeat.com, the stock has a consensus rating of “Buy” and an average target price of GBX 193.33.

Diaceutics Stock Down 1.7%

The company has a debt-to-equity ratio of 0.39, a quick ratio of 9.92 and a current ratio of 4.85. The stock’s 50 day simple moving average is GBX 144.01 and its 200 day simple moving average is GBX 145.84. The firm has a market cap of £143.02 million, a P/E ratio of -93.89 and a beta of 0.58.

Diaceutics Company Profile

At Diaceutics we believe that every patient should get the opportunity to receive the right test and the right therapy to positively impact their disease outcome. We provide the world’s leading pharma and biotech companies with an end-to-end commercialisation solution for precision medicines through data analytics, scientific and advisory services enabled by our platform DXRX – The Diagnostics Network®.